首頁 > 市場調查報告書 > 醫療設備

生物材料

市場調查報告書

商品編碼

1629877

全球生物材料市場 - 2025-2033

Global Biomaterials Market - 2025-2033

出版日期: 2024年12月30日 | 出版商:

DataM Intelligence | 英文 176 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2023年，全球生物材料市場規模達1,773億美元，預估至2033年將達3,999億美元，2025-2033年預測期間複合年成長率為10.7%。

生物材料在醫學中至關重要，可以恢復功能並促進受傷或疾病後的癒合。它們可以是天然的或合成的，用於支持、增強或取代受損的組織或生物功能。生物材料領域結合了醫學、生物學、物理、化學和組織工程，以及再生醫學和組織工程的最新發現。該領域在過去十年中取得了顯著發展。

市場動態：

驅動程式和限制

慢性病盛行率上升

由於心血管疾病、糖尿病、關節炎和癌症等慢性疾病的盛行率不斷增加，全球生物材料市場正在成長。這些疾病需要先進的醫療干預措施，如植入物、義肢、支架和藥物傳輸系統，而這些系統的功能和安全性在很大程度上依賴生物材料。金屬和聚合物基生物材料在骨科植入物和藥物傳輸系統中至關重要。由於需要長期解決方案來管理這些條件，因此加速了對生物相容性和耐用材料的需求。隨著慢性病給全球醫療保健系統帶來壓力，生物材料在改善患者治療效果和實現創新治療方面的作用不斷擴大。

例如，根據國家慢性病預防和健康促進中心的數據，美國有 1,290 億人患有至少一種主要慢性病，包括心臟病、癌症、糖尿病、肥胖和高血壓。美國十大死亡原因中有五個與可預防和可治療的慢性病有關。在過去的二十年中，患病率穩步上升，並且預計這種趨勢將持續下去。越來越多的美國人患有多種慢性病，其中 42% 的人患有兩種或兩種以上，12% 的人患有至少五種慢性病。慢性病也對美國醫療保健系統產生重大影響，佔年度 4.1 兆美元支出的 90%。

因此，生物材料在滿足這些需求方面發揮著至關重要的作用，因為它們是開發旨在有效管理和治療這些疾病的植入物、義肢和藥物傳輸系統的組成部分。

生物材料相關併發症的風險

由於生物材料相關併發症的風險，全球生物材料市場面臨重大挑戰。這些併發症的發生可能是由於材料選擇不當、製造流程不理想或患者特定因素造成的。植入物或設備的故障可能會導致額外的醫療費用、延長治療時間和矯正手術。這些併發症可能會破壞基於生物材料的解決方案的有效性並影響患者的治療結果，從而降低對這些產品的信心。

Biomaterials are essential in medicine, restoring function and facilitating healing after injury or disease. They can be natural or synthetic and are used to support, enhance, or replace damaged tissue or biological functions. The field of biomaterials combines medicine, biology, physics, chemistry, and tissue engineering, with recent discoveries in regenerative medicine and tissue engineering. The field has grown significantly in the past decade.

Market Dynamics: Drivers & Restraints

Rise in the Prevalence of Chronic Diseases

The global biomaterials market is growing due to the increasing prevalence of chronic diseases like cardiovascular diseases, diabetes, arthritis, and cancer. These diseases require advanced medical interventions like implants, prosthetics, stents, and drug delivery systems, which rely heavily on biomaterials for functionality and safety. Metallic and polymer-based biomaterials are crucial in orthopedic implants and drug delivery systems. The demand for biocompatible and durable materials is accelerated by the need for long-term solutions to manage these conditions. As chronic diseases strain healthcare systems globally, biomaterials' role in enhancing patient outcomes and enabling innovative treatments continues to expand.

For instance, according to National Center for Chronic Disease Prevention and Health Promotion the US has 129 Billion people with at least one major chronic disease, including heart disease, cancer, diabetes, obesity, and hypertension. Five of the top 10 leading causes of death in the US are associated with preventable and treatable chronic diseases. Over the past two decades, prevalence has steadily increased, and this trend is expected to continue. An increasing proportion of Americans are dealing with multiple chronic conditions, with 42% having two or more and 12% having at least five. Chronic diseases also significantly impact the US healthcare system, accounting for 90% of annual $4.1 trillion expenditure.

Hence, biomaterials play a vital role in addressing these needs, as they are integral to developing implants, prosthetics, and drug delivery systems designed to manage and treat these conditions effectively.

Risk of Biomaterial-related Complications

The global biomaterials market faces a significant challenge due to the risk of biomaterial-related complications. These complications can occur due to improper material selection, suboptimal manufacturing processes, or patient-specific factors. The failure of implants or devices can lead to additional healthcare costs, extended treatments, and corrective surgeries. These complications can undermine the effectiveness of biomaterial-based solutions and affect patient outcomes, reducing confidence in these products.

Segment Analysis

The global biomaterials market is segmented based on product type, application, end user and region.

Product Type:

Metallic Biomaterials segment is expected to dominate the biomaterials market share

The metallic biomaterials segment holds a major portion of the biomaterials market share and is expected to continue to hold a significant portion of the biomaterials market share during the forecast period.

Metallic biomaterials, primarily made of stainless steel, titanium, and cobalt-chromium alloys, are essential in the global biomaterials market due to their excellent mechanical properties, durability, and biocompatibility. They are commonly used in orthopedic implants, dental implants, cardiovascular stents, and surgical instruments, particularly in load-bearing implants like joint replacements and bone fracture fixation.

Moreover, the demand for metallic biomaterials is growing due to the aging population and increasing prevalence of chronic conditions like arthritis, cardiovascular diseases, and osteoporosis. Advances in surface modification techniques, such as coating metallic biomaterials with biocompatible materials, are driving their use in more complex medical procedures. As these materials evolve, their role in the biomaterials market remains vital for improving healthcare outcomes and patient quality of life.

Application:

Cardiovascular segment is the fastest-growing segment in biomaterials market share

The cardiovascular segment is the fastest-growing segment in the biomaterials market share and is expected to hold the market share over the forecast period.

Cardiovascular segment plays important role in biomaterials as they are crucial in the development of various cardiovascular devices, such as stents, heart valves, pacemakers, and vascular grafts. Metallic biomaterials like titanium and stainless steel are used in stents and pacemakers due to their strength and corrosion resistance. Polymer-based biomaterials are used in heart valve replacements and vascular grafts due to their flexibility and better integration with biological tissues. The demand for biomaterial-based solutions is increasing due to cardiovascular diseases being a leading cause of mortality worldwide. The market for biomaterials in cardiovascular applications is expected to expand due to ongoing advancements in material science and technology.

For instance, in January 2023, Scientists at the University of California have developed a new iomaterial that can be injected intravenously, reduce inflammation, and repair cardiac tissue damage from heart attacks. The biomaterial was tested in a rodent model and proved effective in treating tissue damage caused by heart attacks in both rodent and large animal models. The study suggests the iomaterial could be beneficial for patients with traumatic brain injury and pulmonary arterial hypertension.

Geographical Analysis

North America is expected to hold a significant position in the bomaterials market share

North America holds a substantial position in the biomaterials market and is expected to hold most of the market share due to the its advanced healthcare infrastructure, high healthcare expenditure, and robust medical device industry. The region's focus on research and development, particularly in tissue engineering and regenerative medicine, has led to innovation in biomaterials. The US, particularly the US, is home to leading companies specializing in biomaterial technologies and medical devices, contributing to market growth. The increasing prevalence of chronic diseases and the aging population in North America further amplify the demand for biomaterial-based solutions. High healthcare spending and regulatory support further strengthen the market, making North America a dominant force in the global biomaterials market.

For instance, in January 2024, Xenco Medical showcased its TrabeculeX Continuum at the 2024 Consumer Electronics Show. This technology bridges Digital Health and Biomaterials, combining the FDA-cleared TrabeculeX Bioactive Matrix and the TrabeculeX Recovery App. It unifies a patient's biomaterial implantation and postoperative journey, allowing surgeons to enroll patients in the Recovery App and engage in Remote Therapeutic Monitoring. The TrabeculeX Continuum is an unprecedented intersection of regenerative medicine and digital health.

Europe is growing at the fastest pace in the biomaterials market

Europe holds the fastest pace in the biomaterials market and is expected to hold most of the market share due to the strong healthcare system, growing elderly population, and significant investments in research and innovation. The EU and other countries have established regulations promoting advanced biomaterials, leading to a flourishing medical device industry. Biomaterials are crucial in producing implants, prosthetics, and surgical instruments. The aging population in Europe is a significant driver, as they often experience chronic diseases like cardiovascular disease, osteoarthritis, and diabetes. Europe's leading research institutions and universities focus on biomaterial science, encouraging continuous innovation in materials like bioresorbable stents, tissue-engineered scaffolds, and orthopedic implants.

For instance, in July 2024, UK-based Biotech 4D Medicine has raised £3.4m in a Series A round, led by Oshen Holdings and supported by DSW Ventures, SFC Capital, Boundary Capital, and private investors. The funding will enable the company to complete pre-clinical testing of its first product range and seek FDA clearance for entry into the US market. 4D Medicine, a spin-out from the Universities of Birmingham and Warwick, develops a resorbable biomaterial called 4Degra for implants and soft tissue scaffolds. Preliminary testing shows the biomaterial gradually erodes and is resorbed by normal metabolic processes as natural tissue grows.

Competitive Landscape

The major global players in the biomaterials market include BASF SE, Evonik Industries AG, Royal DSM N.V., Corbion N.V., Zimmer Biomet Holdings, Inc, Medtronic plc, Stryker Corporation, Johnson & Johnson (DePuy Synthes), Smith & Nephew plc, Wright Medical Group N.V. and among others.

Key Developments

In October 2023, The University of Birmingham Enterprise has launched the Birmingham Dental and Biomaterials Testing Service (BiMaTs), a consultancy and comprehensive materials testing service for dental and biomaterial manufacturers. Co-founded by Professor Josette Camilleri and Professor Will Palin, BiMaTs will assess the mechanical and physical properties of materials and the biological properties of material-tissue interfaces, developing tailored protocols for individual clients.

Emerging Players

The emerging players in the biomaterials market include Nexeon MedSystems, NuVasive, Inc, Amastan Technologies, Matexcel, Regenovo Biotechnology Co., Ltd., Bioretec Ltd., Aspect Biosyst and among others and among others.

Why Purchase the Report?

Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
Post-market Surveillance: Uses post-market data to enhance product safety and access.
Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global biomaterials market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
Component & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
Supply Chain: Distribution and Supply Chain Managers.
Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
Academic & Research: Academic Institutions.

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product Type
3.2. Snippet by Application
3.3. Snippet by End User
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Rise in the Prevalence of Chronic Diseases
- 4.1.2. Restraints
  - 4.1.2.1. Risk of Biomaterial-related Complications
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis

6. By Product Type

6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 6.1.2. Market Attractiveness Index, By Product Type
6.2. Metallic Biomaterials*
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Polymeric Biomaterials
6.4. Ceramic Biomaterials
6.5. Natural Biomaterials
6.6. Composite Biomaterials

7. By Application

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 7.1.2. Market Attractiveness Index, By Application
7.2. Cardiovascular*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Orthopedic
7.4. Dental
7.5. Ophthalmology
7.6. Wound Healing
7.7. Neurology
7.8. Others

8. By End User

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 8.1.2. Market Attractiveness Index, By End User
8.2. Hospitals*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Specialty Clinics
8.4. Ambulatory Surgical Centers
8.5. Academic and Research Institutes
8.6. Biotechnology Companies

9. By Region

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 9.1.2. Market Attractiveness Index, By Region
9.2. North America
- 9.2.1. Introduction
- 9.2.2. Key Region-Specific Dynamics
- 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.2.6.1. U.S.
  - 9.2.6.2. Canada
  - 9.2.6.3. Mexico
9.3. Europe
- 9.3.1. Introduction
- 9.3.2. Key Region-Specific Dynamics
- 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.3.6.1. Germany
  - 9.3.6.2. U.K.
  - 9.3.6.3. France
  - 9.3.6.4. Spain
  - 9.3.6.5. Italy
  - 9.3.6.6. Rest of Europe
9.4. South America
- 9.4.1. Introduction
- 9.4.2. Key Region-Specific Dynamics
- 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.4.6.1. Brazil
  - 9.4.6.2. Argentina
  - 9.4.6.3. Rest of South America
9.5. Asia-Pacific
- 9.5.1. Introduction
- 9.5.2. Key Region-Specific Dynamics
- 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 9.5.6.1. China
  - 9.5.6.2. India
  - 9.5.6.3. Japan
  - 9.5.6.4. South Korea
  - 9.5.6.5. Rest of Asia-Pacific
9.6. Middle East and Africa
- 9.6.1. Introduction
- 9.6.2. Key Region-Specific Dynamics
- 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

10. Competitive Landscape

10.1. Competitive Scenario
10.2. Market Positioning/Share Analysis
10.3. Mergers and Acquisitions Analysis

11. Company Profiles

11.1. BASF SE *
- 11.1.1. Company Overview
- 11.1.2. Product Portfolio and Description
- 11.1.3. Financial Overview
- 11.1.4. Key Developments
11.2. Evonik Industries AG
11.3. Royal DSM N.V.
11.4. Corbion N.V.
11.5. Zimmer Biomet Holdings, Inc.
11.6. Medtronic plc
11.7. Stryker Corporation
11.8. Johnson & Johnson (DePuy Synthes)
11.9. Smith & Nephew plc
11.10. Wright Medical Group N.V.

LIST NOT EXHAUSTIVE